Amylyx Pharmaceuticals (AMLX) announced the pricing of an upsized underwritten public offering of 14.09M shares of common stock at $35.50 per share. The total gross proceeds are expected to reach $500.2M before expenses, with closing anticipated on or about August 21, 2026.
